Key clinical point: Increased percentage of mature monocyte in bone marrow (PMMBM) may assist the Revised International Prognostic Scoring System (IPSS-R) to predict poor prognosis in patients with myelodysplastic syndromes (MDS).
Major finding: Elevated (>6%) vs. normal PMMBM was associated with shorter overall survival (24 months vs. 37 months; P = .026) along with higher risk distribution in terms of IPSS-R ( P = .025) and higher frequency of IDH2 mutation ( P = .007).
Study details: The data come from a retrospective analysis of 216 MDS patients, categorized into elevated and normal PMMBM groups.
Disclosures: The study was supported by the Zhejiang Provincial Natural Science Foundation of China, Medical and Health Science and Technology Projects of Zhejiang Province, National Science Foundation of Ningbo, and Chinese Medicine Science and Technology Plan Project of Zhejiang Province. The authors declared no conflicts of interest.
Source: Wu A et al. BMC Cancer. 2021 May 13. doi: 10.1186/s12885-021-08303-8 .